UROGEN PHARMA LTD (URGN) Stock News

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips UroGen Pharma (NASDAQ:URGN) just reported results for the second quarter of 202...

UroGen Pharma Stock Earns 91 RS Rating

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

Mentions: ADMA HALO UTHR

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

UroGen Pharma to Present at Upcoming Investor Conferences

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug

The company is working on a treatment for non-muscle invasive bladder cancer.

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Mentions: YOSH SMX AEHR ATPC ...

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Mentions: PSMT MCY RM ROKU ...

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

UroGen Appoints Chris Degnan as Chief Financial Officer

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing...

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC